© John Wiley & Sons A/S
Edited By: Ron Shapiro, MD
Impact Factor: 1.844
ISI Journal Citation Reports © Ranking: 2015: 16/25 (Transplantation); 78/200 (Surgery)
Online ISSN: 1399-0012
Just Published Articles
- Decisional Conflict between Treatment Options among End-Stage Renal Disease Patients Evaluated for Kidney Transplantation
Laura McPherson, Mohua Basu, Jennifer Gander, Stephen O. Pastan, Sumit Mohan, Michael S. Wolf, Mariana Chiles, Allison Russell, Kristie Lipford and Rachel E. Patzer
Accepted manuscript online: 29 APR 2017 05:50AM EST | DOI: 10.1111/ctr.12991
- Patterns of primary care utilization before and after living kidney donation
Jennifer L. Alejo, Xun Luo, Allan B. Massie, Macey L. Henderson, Sandra R. DiBrito, Jayme E. Locke, Tanjala Purnell, Brian J. Boyarsky, Saad Anjum, Samantha E. Halpern and Dorry L. Segev
Accepted manuscript online: 29 APR 2017 05:50AM EST | DOI: 10.1111/ctr.12992
- You have full text access to this OnlineOpen articlePharmacokinetics of prolonged-release tacrolimus versus immediate-release tacrolimus in de novo liver transplantation: A randomized phase III substudy
Bo-Göran Ericzon, Evaristo Varo, Pavel Trunečka, Lutz Fischer, Michele Colledan, Bruno Gridelli, Andrés Valdivieso, John O'Grady, James Dickinson and Nasrullah Undre
Version of Record online: 27 APR 2017 | DOI: 10.1111/ctr.12958
- Predictors of outcome among patients on extracorporeal membrane oxygenation as a bridge to lung transplantation
Amit Banga, Elizabeth Batchelor, Manish Mohanka, Srinivas Bollineni, Vaidehi Kaza, Jessica Mullins, Melissa Tran, Pietro Bajona, Matthias Peltz, Michael Wait and Fernando Torres
Accepted manuscript online: 26 APR 2017 11:35AM EST | DOI: 10.1111/ctr.12990
- Endoscopic findings following retroperitoneal pancreas transplantation
Alexey Valer'evich Pinchuk, Ilya Victorovich Dmitriev, Nonna Valer'evna Shmarina, Yury Sergeevich Teterin, Aslan Galievich Balkarov, Roman Vasil'evich Storozhev, Yuri Andreevich Anisimov and Ali Magomedovich Gasanov
Accepted manuscript online: 26 APR 2017 01:55AM EST | DOI: 10.1111/ctr.12989
CTR | Transplant Peer Review Network
Clinical Transplantation participates in the Wiley Transplant Peer Review Network
Download today | Clinical Transplantation app
Available in the App StoreSM: iPad®, iPhone®, and iPod touch®
Subscribers: follow the registration wizard for full access.
The Legacy of Thomas E. Starzl, MD, PhD 3/11/1926 – 3/4/2017
One of the great pioneers (some would argue the greatest pioneer) in the history of transplantation passed away in his sleep in the early morning of March 4, 2017, one week shy of his 91st birthday. His accomplishments would have been enough for any 6 incredibly productive careers—over 2200 papers, 1300 lectures, several books, and critical roles in the development of clinical immunosuppression, kidney, liver, pancreas, and small bowel transplantation, and the mentorship of generations of leaders in the field of transplantation. A member of every important surgical and medical society, including the Institute of Medicine and the American Philosophical Society, he received virtually every award imaginable, including the National Medal of Science, the Lasker award, and the Medawar Prize (of the Transplantation Society), with the exception of the Nobel Prize (for which he had been nominated). His contributions to the development of clinical immunosuppression began with the demonstration that azathioprine and prednisone represented a successful approach in kidney transplantation, at a time when any sort of routine engraftment had not yet been achieved. He continued with the demonstration of the efficacy of cyclosporine in liver, kidney, heart, lung, and pancreas transplantation, and the improved efficacy of tacrolimus as an immunosuppressive agent, allowing routine withdrawal or even avoidance of corticosteroids. His perseverance led to the first successful liver transplants, at a time when few shared his conviction that it was achievable. His demonstration of micro chimerism in long surviving kidney recipients and his attempts at tolerogenic immunosuppression and xenotransplantation reflected the diversity of his scientific interests.
There were, however, two fundamental aspects of his world view that directed all of his endeavors, and that remain lessons and a legacy for all of us. First, he was fundamentally a clinician, and everything that he did was focused on improving the welfare of his patients. He celebrated their successes, and mourned their deaths. Second, and perhaps most important, he was never satisfied. Everything could be improved—immunosuppression, technical approaches, minimization of side effects—and he was never complacent about what had been achieved. This unwillingness to accept what had been achieved as the last word was pervasive throughout his career, and drove him to continue to improve everything he touched. His lack of complacence remains an ongoing challenge for those of us who have continued in the field.
Dr. Starzl was an important mentor to just about everyone in the field of transplantation, either directly, or one or two generations removed. His record of accomplishment is humbling to the rest of us, and he is a role model for his dedication and perseverance in the face of criticism and active hostility (new ideas are never easily accepted, and he generated new ideas throughout his career). He will be missed by all of us who knew him and all of the patients whose lives he saved and enriched.
New Content Alerts
Never miss an issue of Clinical Transplantation!
Free, customizable e-mail content alerts notify you of articles or issues as they publish, in the frequency and format you prefer. Sign up today and never miss an issue.Alerts: Log in (top right), then click this icon in the Journal Tools menu (left).